The molecular background of aggressive B cell lymphomas as a basis for targeted therapy

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 275-283

  De Jong, Daphne ^a   Balagué Ponz, Olga ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

B cell; Burkitt; diffuse; gene; genetic; large cell; lymphoma; therapy

Indexed keywords

B CELL LYMPHOMA; BURKITT LYMPHOMA; CHROMOSOME ABERRATION; GENE EXPRESSION; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 78649995921     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2807     Document Type: Review

References (68)

1. WHO Classification of Tumours of Haematological and Lymphoid Tissues. Lyon: IARC Press: 2008.
2. Ashworth A, Bernards R,. Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol 2010; 2: a003327.
3. Bernards R,. It's diagnostics, stupid. Cell 2010; 141: 13-17.
4. Tutt A, Robson M, Garber JE, et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
5. Alizadeh AA, Eisen MB, Davis RE, et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
6. Rosenwald A, Wright G, Chan WC, et al., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
7. Savage KJ, Monti S, Kutok JL, et al., The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 2: 3871-3879.
8. Rosenwald A, Wright G, Leroy K, et al., Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
9. Hasserjian RP, Ott G, Elenitoba-Johnson KS, et al., Commentary on the WHO classification of tumors of lymphoid tissues (2008): 'Gray zone' lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematopathol 2009; 2: 89-95.
10. Quintanilla-Martinez L, de Jong D, de Mascarel A, et al., Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematopathol 2009; 2: 211-236.
11. Davis RE, Brown KD, Siebenlist U, et al., Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
12. Jost PJ, Ruland J,. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700-2707.
13. Lam LT, Davis RE, Pierce J, et al., Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Can Res 2005; 11: 28-40.
14. Ngo VN, Davis RE, Lamy L, et al., A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-110.
15. Lenz G, Davis RE, Ngo VN, et al., Oncogenic CARD11 mutations in human diffuse large B-cell lymphoma. Science 2008; 319: 1676-1679.
16. Compagno M, Lim WK, Grunn A, et al., Mutations in multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
17. Honma K, Tsuzuki S, Nakagawa MY, et al., TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
18. Davis RE, Ngo VN, Lenz G, et al., Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
19. Lenz G, Wright GW, Emre NC, et al., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525.
20. Pinyol M, Cobo F, Bea S, et al., p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-2984.
21. Pinyol M, Hernández L, Martínez A, et al., INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000; 156: 1987-1996.
22. Tagawa H, Suguro M, Tsuzuki S, et al., Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106: 1770-1777.
23. Dunleavy K, Pittaluga S, Czuczman MS, et al., Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076.
24. Shipp MA,. Molecular signatures define new rational treatment targets in large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2007; 265-269.
25. Lossos IS, Alizadeh AA, Eisen MB, et al., Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209-10213.
26. Lenz G, Nagel I, Siebert R, et al., Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007; 204: 633-643.
27. Huang JZ, Sanger WG, Greiner TC, et al., The t(14; 18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.
28. Young KH, Leroy K, Møller MB, et al., Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088-3098.
29. Bea S, Zettl A, Wright G, et al., Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression based survival prediction. Blood 2005; 106: 3183-3190.
30. Kang MH, Reynolds CP,. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
31. Cheson B,. Targeted treatment and new agents in follicular lymphoma. Int J Hematol 2010; 92: 5-11.
32. Lawrie CH, Chi J, Taylor S, et al., Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009; 13: 1248-1260.
33. Li Z, van Calcar S, Qu C, et al., A global transcriptional regulatory role for c-MYC in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-8168.
34. Klapproth K, Wirth T,. Advances in understanding of MYC-induced lymphomagenesis. Br J Haematol 2010; 149: 484-497.
35. O'Donnell KA, Wentzel EA, Zeller K, et al., c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843.
36. Guikema JE, Schuuring E, Kluin PM,. Structure and consequences of IGH switch breakpoints in Burkitt lymphoma. J Natl Cancer Inst Monogr 2008; 39: 32-36.
37. Guikema JE, de Boer C, Haralambieva E, et al., IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination. Genes Chromosomes Cancer 2006; 45: 808-819.
38. Lindström MS, Wiman KG,. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 2002; 12: 381-387.
39. Boerma EJ, Siebert R, Kluin PM, et al., Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas-a historical review of cytogenetics in the light of today's knowledge. Leukemia 2009; 23: 225-234.
40. De Falco G, Leucci E, Lenze D, et al., Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 2007; 110: 1301-1307.
41. Leucci E, Cocco M, Onnis A, et al., MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008; 216: 440-450.
42. Leucci E, Onnis A, Cocco M, et al., B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer 2010; 126: 1316-1326.
43. Robertus JL, Kluiver J, Weggemans C, et al., MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol 2010; 149: 896-899.
44. Bertrand P, Bastard C, Maingonnat C, et al., Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 2007; 21: 515-523.
45. Hummel M, Bentink S, Berger H, et al., A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 254: 2419-2430.
46. Dave SS, Fu K, Wright GW, et al., Molecular diagnosis of Burkitt lymphoma. N Engl J Med 2006; 354: 2431-2442.
47. Salaverria I, Zettl A, Beà S, et al., Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica 2008; 93: 1327-1334.
48. Hoefnagel JJ, Dijkman R, Basso K, et al., Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105: 3671-3678.
49. Dijkman R, Tensen CP, Jordanova ES, et al., Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol 2006; 24: 296-305.
50. Booman M, Szuhai K, Rosenwald A, et al., Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
51. Booman M, Douwes J, Glas AM, et al., Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 2006; 210: 163-171.
52. Ferch U, Kloo B, Gewies A, et al., Inhibition of MALT1 protease activity is selectively toxic for activated B-cell like diffuse large B-cell lymphoma cells. J Exp Med 2009; 2006: 2313-2320.
53. Milhollen MA, Traore T, Adams-Duffy J, et al., MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood 2010; 116: 1515-1523.
54. Workman P, Burrows F, Neckers L, et al., Drugging the cancer chaperone HSP90 combinational therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007; 1113: 202-216.
55. Hans CP, Weisenburger DD, Greiner TC, et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
56. Choi WW, Weisenburger DD, Greiner TC, et al., A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502.
57. de Jong D, Rosenwald A, Chhanabhai M, et al., Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805-812.
58. de Jong D, Xie W, Rosenwald A, et al., Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009; 62: 128-138.
59. Ballabio E, Chi J, Roncador G, et al., Comparison of Choi and Hans' algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR- letter. Clin Cancer Res 2010; 16: 3805-3806.
60. Shipp MA, Ross KN, Tamayo P, et al., Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
61. Monti S, Savage KJ, Kutok JL, et al., Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
62. Takahashi H, Feuerhake F, Kutok JL, et al., FAS death domain deletions and cellular FADD-like interleukin 1β converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res 2006; 12: 3265-3271.
63. Iqbal J, Greiner TC, Patel K, et al., Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007; 21: 2332-2343.
64. Polo JM, Juszczynski P, Monti S, et al., Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007; 104: 3207-3212.
65. Friedberg JW, Sharman J, Sweetenham J, et al., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
66. Chen L, Monti S, Juszczynski P, et al., SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230-2237.
67. Robertson MJ, Kahl BS, Vose JM, et al., Phase II study of enzastaurin, a protein kinase C β inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-1746.
68. Bentink S, Wessendorf S, Schwaenen C, et al., Pathway activation patterns in diffuse large B-cell lymphoma. Leukemia 2008; 22: 1746-1754.